HAVCR2 and neoplasm: Recently, several alternative immune checkpoints in the tumour microenvironment have been targeted to develop new inhibitors or therapeutic agents (under clinical trial) such as anti-LAG-3 antibody [173] and TIM-3 [174] in an attempt to improve the efficacy of immunotherapy.